Syndax Pharmaceuticals, Inc. (SNDX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$39.99M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$34.20M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$57.43M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$69.35M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$39.99M | (m) | $72.79M | (m) | (m) | -$30.27M* | (m) | $68.04M | (m) | $0.00* |
| 2026-03-31 | Reported | (m) | -$34.20M | (m) | $64.86M | (m) | (m) | -$50.34M | (m) | $58.84M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$57.43M | (m) | $45.87M | (m) | (m) | -$70.53M* | (m) | $56.28M | (m) | $0.00* |
| 2025-06-30 | Reported | (m) | -$69.35M | (m) | $37.96M | (m) | (m) | -$87.80M* | (m) | $62.23M | (m) | $0.00* |
| 2025-03-31 | Reported | (m) | -$83.76M | (m) | $20.04M | (m) | (m) | -$95.16M | (m) | $61.64M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$89.58M | (m) | $12.50M | (m) | (m) | -$62.32M* | (m) | $70.97M | (m) | $0.00* |
| 2024-06-30 | Reported | (m) | -$74.22M | (m) | $3.50M | (m) | (m) | -$71.64M* | (m) | $48.66M | (m) | $0.00* |
| 2024-03-31 | Reported | (m) | -$79.51M | (m) | $0.00 | (m) | (m) | -$83.55M | (m) | $56.49M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$56.35M | (m) | $0.00 | (m) | (m) | -$44.65M* | (m) | $39.09M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$49.68M | (m) | $0.00 | (m) | (m) | -$35.37M* | (m) | $34.76M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$46.02M | (m) | (m) | (m) | (m) | -$39.23M | (m) | $34.05M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$35.14M | (m) | (m) | (m) | (m) | -$28.54M* | (m) | $26.90M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$37.72M | (m) | (m) | (m) | (m) | -$40.31M* | (m) | $29.73M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$36.86M | (m) | (m) | (m) | (m) | -$41.93M | (m) | $30.02M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$20.03M | (m) | $12.38M | (m) | (m) | -$24.94M* | (m) | $25.61M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$22.33M | (m) | $379.00K | (m) | (m) | -$24.05M* | (m) | $16.87M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$27.16M | (m) | $379.00K | (m) | (m) | -$22.59M | (m) | $21.87M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$19.86M | (m) | $380.00K | (m) | (m) | (m) | (m) | $15.52M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$19.85M | (m) | $379.00K | (m) | (m) | -$18.30M* | (m) | $14.41M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$16.61M | (m) | $379.00K | (m) | (m) | -$21.41M* | (m) | $10.94M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$15.10M | (m) | $379.00K | (m) | (m) | -$15.93M | (m) | $9.56M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$14.21M | (m) | $380.00K | (m) | (m) | (m) | (m) | $9.50M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$13.15M | (m) | $379.00K | (m) | (m) | -$8.53M* | (m) | $9.92M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$15.37M | (m) | $379.00K | (m) | (m) | -$12.53M* | (m) | $12.29M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$14.81M | (m) | $379.00K | (m) | (m) | -$16.83M | (m) | $11.28M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$19.33M | (m) | $380.00K | (m) | (m) | (m) | (m) | $15.82M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$17.84M | (m) | $379.00K | (m) | $0.00* | -$18.47M* | (m) | $14.10M | (m) | $0.00* |
| 2018-06-30 | Reported | (m) | -$18.95M | (m) | $379.00K | (m) | $0.00* | -$15.15M* | (m) | $14.85M | (m) | $0.00* |
| 2018-03-31 | Reported | (m) | -$19.75M | (m) | $379.00K | (m) | $173.00K | -$19.87M | (m) | $15.34M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$19.49M | (m) | $1.19M | (m) | (m) | (m) | (m) | $16.60M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$15.45M | (m) | $305.00K | (m) | (m) | -$10.18M* | (m) | $12.19M | (m) | $0.00* |
| 2017-06-30 | Reported | (m) | -$13.84M | (m) | $305.00K | (m) | (m) | (m) | (m) | $9.86M | (m) | $0.00* |
| 2017-03-31 | Reported | (m) | -$13.18M | (m) | $305.00K | (m) | (m) | (m) | (m) | $9.55M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$11.14M | (m) | (m) | (m) | (m) | (m) | (m) | $8.47M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$15.24M | (m) | (m) | (m) | $55.00K* | (m) | (m) | $12.27M | (m) | $0.00* |
| 2016-06-30 | Reported | (m) | -$8.63M | (m) | (m) | (m) | $73.00K* | (m) | (m) | $6.13M | (m) | $0.00* |
| 2016-03-31 | Reported | (m) | -$8.75M | (m) | (m) | (m) | $133.00K | (m) | (m) | $4.79M | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$4.68M | (m) | (m) | (m) | (m) | (m) | (m) | $2.59M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$5.86M | (m) | (m) | (m) | $13.00K* | (m) | (m) | $2.97M | (m) | $0.00* |
| 2015-06-30 | Reported | (m) | -$5.54M | (m) | (m) | (m) | (m) | (m) | (m) | $2.27M | (m) | $0.00* |
| 2015-03-31 | Reported | (m) | -$4.43M | (m) | (m) | (m) | (m) | (m) | (m) | $1.72M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$273.08M | (m) | $172.35M | (m) | $187.00K | -$322.98M | (m) | $258.78M | $179.68M | $433.00K |
| 2024-12-31 | Reported | (m) | -$339.67M | (m) | $23.68M | (m) | $0.00 | -$274.90M | (m) | $241.65M | $120.88M | (m) |
| 2023-12-31 | Reported | (m) | -$229.95M | (m) | $0.00 | (m) | $0.00 | -$160.60M | (m) | $163.03M | $66.92M | (m) |
| 2022-12-31 | Reported | (m) | -$151.76M | (m) | $0.00 | (m) | $0.00 | -$133.68M | (m) | $118.50M | $33.26M | (m) |
| 2021-12-31 | Reported | (m) | $26.22M | (m) | $139.71M | (m) | $129.00K | $29.13M | (m) | $88.25M | $25.24M | $0.00 |
| 2021-09-30 | Rolling | (m) | -$89.39M* | (m) | $13.51M* | (m) | (m) | (m) | (m) | $79.87M* | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$89.21M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $68.67M* | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$83.49M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $62.74M* | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$71.42M | (m) | $1.52M | (m) | $0.00 | -$71.26M | (m) | $50.44M | (m) | $0.00 |
| 2020-12-31 | Rolling | (m) | -$71.42M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $50.44M* | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$65.77M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $44.41M* | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$59.06M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $39.93M* | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$57.83M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $41.28M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$57.54M | (m) | $1.52M | (m) | (m) | -$50.61M | (m) | $42.99M | (m) | $0.00 |
| 2019-12-31 | Rolling | (m) | -$57.54M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $42.99M* | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$62.67M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $49.31M* | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$67.36M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $53.48M* | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$70.94M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $56.05M* | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$75.88M | (m) | $1.52M | (m) | $187.00K | -$68.53M | (m) | $60.11M | (m) | $0.00 |
| 2018-12-31 | Rolling | (m) | -$75.88M* | (m) | $1.52M* | (m) | (m) | (m) | (m) | $60.11M* | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$76.03M* | (m) | $2.33M* | (m) | (m) | (m) | (m) | $60.88M* | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$73.64M* | (m) | $2.26M* | (m) | (m) | (m) | (m) | $58.98M* | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$68.53M* | (m) | $2.18M* | (m) | (m) | (m) | (m) | $53.99M* | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$61.95M | (m) | $2.11M | (m) | $84.00K | -$47.37M | (m) | $48.20M | (m) | $0.00 |
| 2017-12-31 | Rolling | (m) | -$61.95M* | (m) | $2.11M* | (m) | (m) | (m) | (m) | $48.20M* | (m) | (m) |
| 2017-09-30 | Rolling | (m) | -$53.61M* | (m) | (m) | (m) | (m) | (m) | (m) | $40.08M* | (m) | (m) |
| 2017-06-30 | Rolling | (m) | -$53.40M* | (m) | (m) | (m) | (m) | (m) | (m) | $40.16M* | (m) | (m) |
| 2017-03-31 | Rolling | (m) | -$48.19M* | (m) | (m) | (m) | (m) | (m) | (m) | $36.43M* | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$43.77M | (m) | $1.22M | (m) | $261.00K | -$35.16M | (m) | $31.66M | (m) | $0.00 |
| 2016-12-31 | Rolling | (m) | -$43.77M* | (m) | (m) | (m) | (m) | (m) | (m) | $31.66M* | (m) | (m) |
| 2016-09-30 | Rolling | (m) | -$37.30M* | (m) | (m) | (m) | (m) | (m) | (m) | $25.78M* | (m) | (m) |
| 2016-06-30 | Rolling | (m) | -$27.92M* | (m) | (m) | (m) | (m) | (m) | (m) | $16.47M* | (m) | (m) |
| 2016-03-31 | Rolling | (m) | -$24.83M* | (m) | (m) | (m) | (m) | (m) | (m) | $12.61M* | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$20.51M | (m) | (m) | (m) | $49.00K | (m) | (m) | $9.55M | (m) | $0.00 |
| 2015-12-31 | Rolling | (m) | -$20.51M* | (m) | (m) | (m) | (m) | (m) | (m) | $9.55M* | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$21.33M | (m) | (m) | (m) | $4.00K | (m) | (m) | $10.18M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |